DaVita Inc. (NYSE: DVA), a leading provider of kidney care services committed to improving the quality of life for those diagnosed with chronic kidney disease (CKD), announced today that it has closed its acquisition of DSI Renal, Inc. ("DSI").
DaVita previously announced the signing of the Merger Agreement for this acquisition on Feb. 4, 2011. The closing follows the Federal Trade Commission's issuance of a consent order approving the closing of the acquisition, conditioned on DaVita's divestiture of 30 clinics (the majority of which were acquired from DSI). Specifically, DaVita will be divesting these clinics for $91 million subject to certain adjustments.
DaVita Chairman and CEO Kent Thiry stated, "The DaVita Village is excited to welcome the good people of DSI. We look forward to being able to bring the broader line of DaVita chronic kidney disease services to DSI patients, and we believe that this combination will enhance our ability to meet the needs of patients, physicians, payors and taxpayers over the long-term."
NIH grants $2.6 million to explore the effects of high blood-pressure drugs in CKD patients